Pannier B E, Garabedian V G, Madonna O, Fouchard M, Darne B, Safar M E
Department of Internal Medicine, Broussais Hospital, Paris, France.
Cardiovasc Drugs Ther. 1991 Aug;5(4):775-81. doi: 10.1007/BF03029754.
In a multicenter, parallel, double-blind study, lisinopril, a new converting enzyme inhibitor, was compared with atenolol in the treatment of mild to moderate essential hypertension. Four hundred ninety patients were randomized to once-a-day treatment with lisinopril 20 mg or atenolol 50 mg for 4 weeks, and the doses of lisinopril or atenolol were increased at 4-week intervals up to 80 mg or 200 mg, respectively, if sitting diastolic blood pressure (SDBP) was not well controlled. Lisinopril and atenolol reduced SDBP to a similar extent. All reductions from baseline in sitting diastolic and systolic blood pressure were significant (p less than 0.01). Lisinopril produced a significantly greater reduction (p less than 0.01) in sitting systolic blood pressure (SSBP) than atenolol. The predominant reduction in SSBP could not be explained on the basis of age, race, or severity of hypertension. It is suggested that the increase in arterial compliance reported for converting enzyme inhibitors could explain the predominant decrease in systolic blood pressure.
在一项多中心、平行、双盲研究中，将新型转换酶抑制剂赖诺普利与阿替洛尔用于轻至中度原发性高血压的治疗，并进行比较。490例患者被随机分为两组，分别接受每日一次的赖诺普利20mg或阿替洛尔50mg治疗，为期4周。如果坐位舒张压（SDBP）控制不佳，则每隔4周增加赖诺普利或阿替洛尔的剂量，分别增至80mg或200mg。赖诺普利和阿替洛尔降低SDBP的程度相似。坐位舒张压和收缩压较基线的所有降低均具有显著性（p<0.01）。赖诺普利使坐位收缩压（SSBP）降低的幅度显著大于阿替洛尔（p<0.01）。SSBP的主要降低不能用年龄、种族或高血压严重程度来解释。提示转换酶抑制剂所报道的动脉顺应性增加可以解释收缩压的主要降低。
